First-Line Treatment Strategies in Metastatic Renal Cell Carcinoma
Key Points
- First-line treatment for metastatic renal cell carcinoma (mRCC) has largely stabilized around immune checkpoint inhibitor (IO) doublets or IO plus tyrosine kinase inhibitor (TKI) combinations.
- IO doublet regimens may offer more durable responses and long-term survival plateaus, while IO/TKI combinations produce higher overall response rates (ORRs) that may be useful for patients with high disease burden.
- Treatment selection requires balancing efficacy and toxicity, with clinicians stressing the importance of demonstrating an overall survival (OS) benefit.
While new treatment strategies for metastatic RCC continue to be investigated, two approaches remain the foundation for current practice: immune checkpoint inhibitor doublets or combinations of immunotherapy and TKIs. Nicholas Simon, MD, of Georgetown MedStar, provided this insight during a discussion with Andre Kydd, MD, PhD, of Fox Chase Cancer Center, at an event coinciding with the 2026 ASCO Genitourinary Cancers Symposium.
Clinical benefit is a key distinction between the two regimens. For instance, IO doublet therapy has demonstrated durable complete responses and long-term survival plateaus in some patients. In contrast, IO/TKI combinations may achieve higher ORRs, although some responses may be less durable, according to Dr. Simon.
He added that clinicians should weigh the added complexity and toxicity associated with multi-drug regimens. When discussing options with patients, clinicians should carefully consider whether a regimen meaningfully improves OS to avoid additional toxicities.